I have a strong personal belief that we are capable of curing any disease and healing all forms of suffering. I trust in providing comprehensive care to rare disease patients. What makes me an integral part of this infinite life-science eco-system? It is the unique idea that the timely and costly drug development process may become fun if only we can increase Key Opinion Leaders (KOLs) understanding of what it truly means to be blind. By connecting patients to KOLs we increase everyone’s engagement.
Shall we provide more knowledge on the significance of basic needs that blind people have, tools they use, assistive technologies, white canes? …- we will make us innovative drivers for novelty. Shall we emphasize the importance of guide dogs? …- we will stay connected to our honest emotional motivations. Shall we accentuate the necessity of reading braille and education? …- we-the visually healthy– open ourselves up to the advantage of approaching scientific problems, and finding solutions differently. Allowing for empathy while maintaining high corporate & legal standards makes us outstanding pioneers in innovation and safety throughout the entire process of bringing new therapies to life.
When I close my eyes the world becomes complete darkness. Not being able to see all the once I love, being unable to admire the beauty of a raising rainbow, yellow sun, and bright stars on a summer night, I only hope that …it is temporary. Your newborn baby – the love and life you poured into its tiny perfect body- is losing sight. She/he will enter the worlds of blank spaces in a few years. Like most parents, you have probably never known anyone who was blind. Yet, here you are. A deficit in knowledge delays the diagnosis of this rare condition. It is genetic and there is currently no cure for it. – Now what?
Leber’s congenital amaurosis (LCA) is an inherited retinal disease that causes severe visual impairment in infancy or early childhood.
Dr Szyszka obtained her MS, with Honors, from the University of Gdansk in Poland and her Ph.D. in Analytical Chemistry (MALDI TOF-MS) from Drexel University in the USA, in 2012. She has broad experiences in Advancing Translational Sciences, with a focus on investigational technologies for the treatment of rare diseases.
She started her career in 2003 as a research intern at Arkema’s U.S. headquarters, the main research, and development location in King of Prussia, USA. She later moved to gain expertise as an analytical chemist at Polpharma S.A current leader of the generic pharmaceutical market. She worked there until 2007. She then decided to pursue her Ph.D. degree at Drexel University in Philadelphia, where she spent her time until 2012. Since then she has worked in scientific and leadership roles at corporate, global organizations, as well as start-ups, including Cordis Corporation- A Johnson and Johnson Compay (PA, USA), Pharmaceutical Research Institute (PL), ProQR Therapeutics B.V. (NL), and Pall Life Sciences (UK).
She paved her path to success with hard work and dedication. She switched to become Chief Visionary Officer at E&ILCA an enterprise she founded and has been developing since 2016.
Being in her early 40s, she is leading in the strategic planning and global liaising for Advanced Translation for the LCA treatments worldwide. With her patient-centric approach, she is involved in bridging basic research and fundamental studies, with clinical implementation and post-market authorization.
Her most powerful attributes are global Executive Leadership and a deep passion for research and innovation. She develops businesses from bottom up. With her entrepreneurial mindset, she manages to gracefully turn monstrous obstacles into great opportunities. Humble as a person, with both feet strongly on the ground.
Professional Recognition & Personal Development
- Introduction to Rare Diseases produced by Ågrenska September 17 2021 (pdf).
- How the oligonucleotide and peptide industries are shifting – INDUSTRY VOICES, May 29 2018.
- Rejected. Applied for a job and did not get accepted. Ouch!. June 7 2017.
- ISPOR Asia Consortium Pharmaceuticals & Biologics Committee/ Health Technology Producers (Industry) Committee, March 6 2017.